Immunotherapy and hormone combo aims to tackle incurable prostate cancer
NCT ID NCT02020070
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether combining the immunotherapy drug ipilimumab with the hormone therapy degarelix, given before and after prostate removal surgery, can control advanced prostate cancer. It includes two groups: men with newly diagnosed cancer that has spread to a few other sites, and men whose cancer has returned after initial treatment. The main goal is to see if this approach can make PSA levels undetectable at 12 and 20 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab and degarelix
- What this could lead to
- If successful, this combination of hormone therapy and immunotherapy could offer a new treatment path for men with prostate cancer that has spread but is still hormone-sensitive.
- What could go wrong
- This is an early-phase trial with only 16 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart scans may slash radiation doses for metastatic prostate cancer
- New drug cocktail shows promise for tough prostate cancer
- Vaccine-Chemo combo shows promise against spread prostate cancer
- New hope for aggressive prostate cancer: carboplatin combo tested in phase 3 trial
- Double scan strategy aims to unlock prostate cancer secrets
- Real-World data reveals treatment patterns for advanced prostate cancer